<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906006</url>
  </required_header>
  <id_info>
    <org_study_id>ABP-671-101</org_study_id>
    <nct_id>NCT03906006</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of ABP-671 in Healthy Volunteers in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      • To assess the safety and tolerability of single ascending oral doses of ABP-671 in Healthy
      Volunteers (HVs).

      Secondary Objectives:

      • To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of single
      ascending oral doses of ABP-671 in HVs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>baseline to 7 days</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose</measure>
    <time_frame>baseline to 7 days</time_frame>
    <description>Maximum tolerable dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum and urine uric acid</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>level of serum and urine uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum and urine creatinine</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>level of serum and urine creatinine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>ABP-671, Cohort 1-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent tablet or placebo during dose escalation (6 active: 2 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-671, Cohort 2-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent oral solution or placebo during dose escalation (6 active: 2 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-671, Cohort 3-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent oral solution or placebo during dose escalation (6 active: 2 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-671, Cohort 4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent oral solution or placebo during dose escalation (6 active: 2 placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP-671</intervention_name>
    <description>Drug: ABP-671, single oral dose</description>
    <arm_group_label>ABP-671, Cohort 1-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 2-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 3-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 4-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Other: Placebo, single oral dose</description>
    <arm_group_label>ABP-671, Cohort 1-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 2-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 3-</arm_group_label>
    <arm_group_label>ABP-671, Cohort 4-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Healthy (no clinically significant health concerns), as determined by medical history,
             physical examination, 12-lead ECG, and vital signs.

          2. Participants serum uric acid level at screening ≥ 4.0 mg/dL to ≤ 5.5 mg/dL for males,
             and ≥ 4.0 mg/dL to ≤ 5.0 mg/dL for females.

          3. Participants must have a body mass index (BMI) between 18 and 32 kg/m2 and a body
             weight of 50 kg or higher.

          4. Participants must have normal blood chemistry or results considered not clinically
             significant by the investigator including electrolytes, alkaline phosphatase, total
             protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             total bilirubin, uric acid, creatinine, blood urea nitrogen (BUN), and glucose at
             Screening Visit and at Pre-dose Visit.

          5. Participants are able to understand the study procedures and risks involved and must
             provide signed informed consent to participate in the study.

        Exclusion Criteria

          1. Participants with any history or clinical manifestations of significant metabolic,
             hematological, pulmonary, including latent tuberculosis, cardiovascular,
             gastrointestinal including cholecystectomy, neurologic, hepatic, renal, urological, or
             psychiatric disorders.

          2. Participants who have any history or suspicion of kidney stones.

          3. Participants who have used prescription drugs, over-the-counter drugs, or herbal
             remedies within 14 days before Day 1 of study medication dosing. Females who have
             received hormone replacement therapy (HRT) within 28 days prior to dosing.

          4. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Armas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gout</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

